Skip to main content
The FASEB Journal logoLink to The FASEB Journal
. 2018 Aug 10;33(1):996–1007. doi: 10.1096/fj.201800614R

Endothelin-1 differentially directs lineage specification of adipose- and bone marrow–derived mesenchymal stem cells

Ming-Song Lee *,†, Jesse Wang *,†, Huihua Yuan *,‡, Hongli Jiao *, Tsung-Lin Tsai *,†, Matthew W Squire *, Wan-Ju Li *,†,1
PMCID: PMC6355080  PMID: 30096039

Abstract

Blood vessels composed of endothelial cells (ECs) contact with mesenchymal stem cells (MSCs) in different tissues, suggesting possible interaction between these 2 types of cells. We hypothesized that endothelin-1 (ET1), a secreted paracrine factor of ECs, can differentially direct the lineages of adipose-derived stem cells (ASCs) and bone marrow–derived MSCs (BMSCs). Predifferentiated ASCs and BMSCs were treated with ET1 for 2 cell passages and then induced for multilineage differentiation. Our results showed that adipogenesis of ET1-pretreated ASCs and osteogenesis of ET1-pretreated BMSCs were increased compared to those of control cells. The effect of ET1 on enhancing adipogenesis of ASCs and osteogenesis of BMSCs was attenuated by blocking endothelin receptor type A (ETAR) and/or endothelin receptor type B (ETBR). Western blot analysis indicated that regulation by ET1 was mediated through activation of the protein kinase B and ERK1/2 signaling pathways. We analyzed subpopulations of ASCs and BMSCs with or without ETAR and/or ETBR, and we found that ETAR+/ETBR− and ETAR−/ETBR+ subpopulations of ASCs and those of BMSCs pretreated with ET1 were prone to turning into adipocytes and osteoblasts, respectively, after differentiation induction. Our findings provide insight into the differential regulation of MSC specification by ET1, which may help develop viable approaches for tissue regeneration.—Lee, M.-S., Wang, J., Yuan, H., Jiao, H., Tsai, T.-L., Squire, M. W., Li, W.-J. Endothelin-1 differentially directs lineage specification of adipose- and bone marrow–derived mesenchymal stem cells.

Keywords: endothelin receptor, adipogenesis, osteogenesis, regenerative medicine


It is crucial to understand how stem cells are regulated by their microenvironment for enhancing outcomes of cell therapies or tissue engineering. Studies have shown that the use of mesenchymal stem cells (MSCs) is considered promising for clinical applications (1, 2) because the cell does not cause issues of immunogenicity and ethics compared to embryonic stem cells (3) and is capable of multilineage differentiation including osteogenesis, chondrogenesis, and adipogenesis (4). Generation of tissues from MSCs holds great potential for tissue repair and wound healing (5). Furthermore, MSCs can be isolated from a variety of tissues, such as bone marrow, fat, and muscle, suggesting that the cell is ubiquitous in many human tissues (6).

Several studies have revealed that bone marrow–derived MSCs (BMSCs) and adipose-derived stem cells (ASCs) reside in tissue-specific niches with environmental cues that help maintain their properties and regulate cell fate (7, 8). The regulation of MSCs by environmental cues from soluble factors and the extracellular matrix has been extensively studied, but how the cell is regulated by its surrounding cells remains less investigated. Within their microenvironment, MSCs are physically contacted with or surrounded by blood vessels (9). Recent studies have even suggested that MSCs are pericytes (10, 11). Although the pericyte identity of MSCs is still under debate, it seems certain that MSCs and blood vessels are together in the microenvironment of different tissues, such as ASCs in the niche of human fat tissue and BMSCs in that of mouse bone marrow (9, 12). Given that blood vessels are composed of endothelial cells (ECs), it is suggested that MSCs may closely interact with ECs and their secreted factors.

ECs can regulate MSCs through paracrine and juxtacrine signaling to influence MSC activities and properties (13). Studies have shown that ECs can secrete molecules, such as platelet-derived growth factor BB (PDGF-BB), vascular endothelial growth factor, epidermal growth factor, and endothelin-1 (ET1) to regulate proliferation and differentiation of stem cells (14, 15). For instance, Lin et al. (16) have demonstrated that endothelial colony-forming cells secrete PDGF-BB to enhance adipogenesis in ASCs, osteogenesis in BMSCs, and proliferation in both of the cell types. We have also found that MSCs cocultured with ECs are primed to differentiate into the osteo and chondro lineages through induction of ET1 (17).

ET1, a 21 aa long peptide originally isolated from the supernatant of porcine aortic ECs, is characterized as a vasoconstrictor (18). ET1 can increase bone formation by elevating proliferation of osteoblasts (19) and modulates voltage-dependent ion channels in transfected Xenopus oocytes and COS-7 cells to induce vasoconstriction (20, 21). Studies have also shown that ET1 binds to endothelin receptor type A (ETAR) and/or endothelin receptor type B (ETBR) to activate signaling pathways, such as protein kinase B (AKT) and ERK (22). For example, activation of ETAR regulates the downstream pathways involving molecules like protein kinase C and mitogen-activated protein kinase (MAPK) to enhance cell proliferation and migration (23, 24) or AKT to promote cell survival, growth, and migration (25). Activation of ETBR can also regulate the ERK pathway to enhance cell proliferation and survival (26) or the AKT pathway to promote vascularization and tumor cell invasion (27). We have also shown that ET1 can enhance osteogenic and chondrogenic differentiation of MSCs through the AKT signaling pathway (17). However, the role of receptors in regulating lineage-specific commitment of MSCs remains unclear.

ASCs and BMSCs are different types of tissue-derived MSCs that hold great potential for regenerative medicine applications. Both cells are capable of undergoing multilineage differentiation into a variety of connective tissue cells. Surface markers, such as CD13, CD29, CD44, CD71, CD73, CD90, CD105, and CD271, are found on both ASCs and BMSCs (28), but others, such as CD36 and CD49d, are only expressed on ASCs, and CD106 is only expressed on BMSCs (29, 30). In addition, the 2 types of cells demonstrate different properties and functions (31, 32), and when induced by the same molecule, they respond differently. For example, Diekman et al. (33) have shown that distinct extents of chondrogenesis in ASCs and BMSCs are induced to produce different amounts of collagen type 2 and aggrecan.

In this study, we hypothesized that ET1 can differentially direct lineage-specific differentiation of ASCs and BMSCs. To test the hypothesis, multilineage differentiation of ET1-pretreated ASCs and BMSCs was analyzed and the roles of ETAR and ETBR in directing lineage-specific differentiation were determined.

MATERIALS AND METHODS

Isolation and culture of ASCs and BMSCs

Human ASCs isolated from 2 female donors (36 and 37 yr old) and 1 male donor (33 yr old) were obtained from a commercial source (Lonza, Basel, Switzerland) and used in this study when they were at cell passage 1. Human BMSCs were isolated from bone marrow of the femoral head and shaft of 2 female donors (25 and 36 yr old) and 1 male donor (47 yr old) undergoing total hip arthroplasty. The cell isolation protocol was approved by the institutional review board at the University of Wisconsin, Madison. Cells from each donor were cultured and assayed independently. ASCs were maintained following the instructions provided by Lonza, and BMSCs were prepared following our previously published protocol (34). Briefly, collected bone marrow was mixed with DMEM (Thermo Fisher Scientific, Waltham, MA, USA). An 18-gauge needle syringe was used to separate a mixture of bone marrow/DMEM from bone debris. The mixture was then centrifuged at 1000 rpm for 5 min before the supernatant was removed and the remaining cell pellet was reconstituted with 25 ml of HBSS (Thermo Fisher Scientific). The reconstituted cell solution was then added to 20 ml of Ficoll solution (GE Healthcare, Chicago, IL, USA) and centrifuged at 500 g for 30 min to create a density gradient. The central layer consisting of mononuclear cells was collected and seeded in T75 flasks with basal culture medium. Both ASCs and BMSCs were cultured with basal medium composed of low-glucose DMEM, 10% fetal bovine serum (FBS; Atlanta Biologicals, Atlanta, GA, USA), and antibiotics, and maintained at 37°C under a humidified atmosphere of 5% CO2. When reaching 70–80% confluence, cells were trypsinized using 0.05% trypsin/EDTA (Thermo Fisher Scientific) and replated at 1000 cells/cm2. Cell culture medium was changed every 3 d.

Cell proliferation analysis

Proliferation of ASCs and BMSCs in culture with or without 0.01 µM of ET1 (Tocris Bioscience, Bristol, United Kingdom) was analyzed. At d 2, 4, and 8, DNA was extracted from cells using Proteinase K (MilliporeSigma, Burlington, MA, USA) and quantified using the PicoGreen assay (Thermo Fisher Scientific) according to the manufacturer’s instructions.

Multilineage differentiation of ASCs and BMSCs

To determine the effect of ET1 on multilineage differentiation of ASCs and BMSCs, cells were treated with 0.01 µM ET1 for 2 passages and then induced for adipo-, osteo-, and chondrogenesis for 21 d without ET1 supplementation, following our previously published protocol (17). ETAR antagonist BQ123, ETBR antagonist BQ788, dual endothelin receptor antagonist Bosentan, AKT inhibitor, or ERK1/2 inhibitor PD98059 were added in culture 30 min before ET1 treatment every 3 d for 2 passages before differentiation induction of MSCs. For adipogenesis, cells were trypsinized and seeded at the density of 10,000 cells/cm2 in culture with adipogenic medium composed of high-glucose DMEM, 10% FBS, 1% antibiotics, 1 µM dexamethasone (MilliporeSigma), 0.5 mM 3-isobutyl-1-methylxanthine, and 1 µg/ml insulin (MilliporeSigma). For osteogenesis, cells were seeded at the density of 5000 cells/cm2 and induced with the medium consisting of low-glucose DMEM, 10% FBS, 1% antibiotics, 10 mM β-glycerophosphate, 50 μg/ml l-ascorbic acid–2-phosphate, and 0.1 µM dexamethasone. For chondrogenesis, 250,000 cells were collected and centrifuged at 600 g for 5 min to form a high-cell-density pellet before induced by chondrogenic medium containing high-glucose DMEM, 1% antibiotics, ITS Premix (BD Biosciences, Franklin Lakes, NJ, USA), 0.9 mM sodium pyruvate (MilliporeSigma), 50 μg/ml l-ascorbic acid-2-phosphate, 40 μg/ml l-proline, 0.1 µM dexamethasone, and 10 ng/ml transforming growth factor-β 1 (PeproTech, Rocky Hill, NJ, USA). Medium was changed every 3 d during the culture period.

To analyze adipogenic differentiation, cells were fixed in 4% formaldehyde and then stained with Oil Red O (MilliporeSigma) for lipid droplet detection. After image analysis, 100% isopropanol was used to dissolve the Oil Red O stain, and absorbance of the resulting solution at 656 nm was measured by a spectrophotometer to determine lipid content. To analyze osteogenic differentiation, cells were fixed in 60% isopropanol and stained with Alizarin Red S (Rowley Biochemical, Danvers, MA, USA) to evaluate mineral deposition. Calcium deposits were extracted using 0.5 M hydrochloric acid and then measured by the LiquiColor Kit (Stanbio, Boerne, TX, USA) according to the manufacturer’s instructions. To examine chondrogenic differentiation, cell pellets were fixed in 4% formaldehyde, dehydrated by a series of gradient ethanol, infiltrated with xylene, and then embedded in paraffin. Embedded cell pellets were cut into 8-μm sections with a microtome and then stained with Alcian Blue (Polysciences, Warrington, PA, USA) to analyze the localization of glycosaminoglycan (GAG). In addition, we quantified the GAG content by digesting cell pellets with papain and detected it with the dimethylmethylene blue assay following a previously described protocol (17). The total GAG amount was normalized with the DNA content measured separately by the PicoGreen assay.

Total RNA extraction and real-time quantitative PCR

Total RNA was extracted from cells using the Nucleo Spin RNA II Kit (Clontech Laboratories, Mountain View, CA, USA). The quantity and quality of total RNA were measured by Nanodrop 1000 (Thermo Fisher Scientific) before the RNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific) for real-time quantitative PCR. The mRNA expression of genes of interest was determined using the iQ SYBR Green Premix (Bio-Rad, Hercules, CA, USA) and the primers to detect fat-associated [peroxisome proliferator-activated receptor γ 2 (PPARG2), adiponectin (APN), and lipoprotein lipase (LPL)], bone-associated [integrin binding sialoprotein (IBSP), osteonectin (ON), and osteopontin (OPN)], and cartilage-associated [sex-determining region Y-box 9 (SOX9), aggrecan (AGN), and COL2] markers as well as ubiquitin C (UBC) as a housekeeping gene (Table 1). The level of mRNA expression was calculated using the 2−ΔCt method with reference to the control UBC.

TABLE 1.

Primer sequences for real-time quantitative PCR analysis

Gene Accession no. Primer sequence, 5′–3′
Forward Reverse
UBC NM_021009.4 TGAAGACACTCACTGGCAAGACCA CAGCTGCTTTCCGGCAAAGATCAA
ON NM_001309443.1 TGCCTGATGAGACAGAGGTG TCCACCTGGACAGGATTAGC
IBSP NM_004967.3 CCATTCTGGCTTTGCATCCG GGGACAAGAAGCCTATTACTTTGC
APN NM_001177800.1 GACCAGGAAACCACGACTCA TTTCACCGATGTCTCCCTTAGG
SOX9 NM_000346.3 TAAAGGCAACTCGTACCCAA ATTCTCCATCATCCTCCACG
PPARG2 NM_138711.3 ATGACAGCGACTTGGCAATA GGCTTGTAGCAGGTTGTCTT
LPL NM_000237.2 AGGAGCATTACCCAGTGTCC GGCTGTATCCCAAGAGATGGA
OPN NM_001040058.1 CGCAGACCTGACATCCAGTA ATGGCCTTGTATGCACCATT
AGN NM_013227.2 CACGATGCCTTTCACCACGAC TGCGGGTCAACAGTGCCTATC
COL2 NM_001844.4 CCTCTGCGACGACATAATCT CTCCTTTCTGTCCCTTTGGT

Flow cytometry, cell sorting, and single cell immunofluorescence analysis

Cells were analyzed by the FACSCalibur flow cytometer (BD Biosciences) to detect the expression of ETAR and ETBR, and fluorescent images of single cells were taken by the ImageStream Mark II Imaging Flow Cytometer (Amnis, Seattle, WA, USA). To prepare purified ETAR+ and ETBR+ cell subpopulations for culture, cells were sorted by the FACSAria Cell Sorter (BD Biosciences). Specifically, trypsinized cells were washed 3 times with ice-cold PBS containing 0.1% sodium azide and 2% serum for flow cytometry, 1% bovine serum albumin, 5 mM EDTA, and 25 mM HEPES. For flow cytometry and fluorescence-activated cell sorting (FACS), cells were treated with the primary antibody rabbit anti-human ETAR and sheep anti-human ETBR (1:30 dilution) (R&D Systems, Minneapolis, MN, USA) for 30 min at 4°C, washed 3 times, then incubated with the secondary antibody NorthernLights anti-rabbit IgG-NL493 and NorthernLights anti-sheep IgG-NL637 (R&D Systems) (1:200 dilution) for 30 min at 4°C. After collection by FACS, sorted cells were transferred into a 50 ml conical tube filled with 37°C basal MSC culture medium and then placed on a continuous shaker for 30 min to remove the antibodies from the cells. The sorted cells were then seeded in tissue culture plates with 0.01 μM ET1 for 2 passages before adipogenic or osteogenic induction. Data of flow cytometry were analyzed by FlowJo (Treestar, Ashland, OR, USA) and fluorescent images were analyzed using Inspire (Amnis).

Western blot analysis

Cells treated with or without ET1 for 1 h were lysed using RIPA buffer composed of 50 mM Tris-HCl pH 7.5, 0.25% Na-deoxycholate, 1% nonidet P-40, 150 mM NaCl, 1 mM EDTA, and complete protease inhibitor cocktail (Roche Life Science, Indianapolis, IN, USA) and then centrifuged at 14,000 rpm for 10 min to extract proteins. The concentration of proteins was measured using the BCA protein kit (Pierce, Rockford, IL, USA) before 40 µg of the protein was mixed with sample buffer at 1:1 and incubated at 90°C for 5 min. Protein samples were then loaded into a 10% polyacrylamide gel (Bio-Rad) for electrophoresis and then transferred to a PVDF membrane (Bio-Rad). The blotted membrane was incubated with primary antibodies detecting GAPDH, phospho-AKT (Ser473), AKT, phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204), and p44/42 MAPK (ERK1/2) (Cell Signaling Technology, Danvers, MA, USA) in blocking buffer composed of Tris-buffered saline, 5% nonfat milk (Bio-Rad), and 0.1% Tween 20 (MilliporeSigma) overnight at 4°C. After unbounded primary antibodies were removed, the membrane was incubated with the horseradish peroxidase–linked secondary antibody (Cell Signaling Technology) for 1 h and then detected by SuperSignal West Pico Chemiluminescent Substrate (Pierce). The Kodak Image Station 4000R Pro System (Kodak, Rochester, NY, USA) was used for image analysis of protein bands.

Statistical analysis

Experimental assays were performed using samples from 3 donors per cohort as biologic replicates. All quantitative data were collected from 3 technical replicates, and data are presented as means ± sd. Statistical comparison between groups was analyzed by a Student’s t test or 1-way ANOVA with a post hoc Tukey’s test. A value of P < 0.05 was considered statistically significant.

RESULTS

Cells treated with ET1 exhibit similar morphology and proliferation

Cell morphology of ASCs and BMSCs treated with ET1 for 2 passages was similar to that of the cells without ET1 treatment, exhibiting elongated spindle shapes (Fig. 1A). In addition, the results of cell proliferation measured in DNA content showed no statistical difference between ASCs and BMSCs at each time point (Fig. 1B), suggesting that ET1 treatment does not change cell proliferation during the culture period.

Figure 1.

Figure 1

Effects of ET1 on ASCs and BMSCs. A) Cell morphology of ASCs and BMSCs after 8 d of culture with or without ET1 induction. B) Proliferation of cells measured by DNA content at different time points in culture with or without ET1 treatment; n = 3. Scale bar, 200 µm.

ET1 primes ASCs for adipogenic differentiation

Cells treated with ET1 for 2 passages before being cultured in adipogenic differentiation medium without ET1 for 21 d were collected for analysis. Oil Red O staining showed that more oil droplets were produced in ASCs pretreated with ET1 than those without ET1 pretreatment, whereas comparable amounts of oil droplets were localized between BMSCs with and without ET1 pretreatment (Fig. 2A). In addition to the qualitative analysis, colorimetric measurement was performed to quantify the amount of lipid droplets by extracting the Oil Red O stain from culture. The results revealed consistent findings that there was significantly more staining in the ET1-pretreated ASC culture than in the control culture, whereas similar levels of staining were found between BMSCs pretreated with and without ET1 (Fig. 2B). The results of mRNA expression showed that levels of most of the fat-related markers PPARG2, APN, and LPL in ET1-pretreated ASCs were significantly higher than those in control cells after 21 d of adipogenic induction. However, BMSCs pretreated with or without ET1 and then induced for adipogenesis expressed comparable levels of PPARG2, APN, and LPL (Fig. 2C).

Figure 2.

Figure 2

Adipogenic differentiation of ET1-pretreated ASCs and BMSCs. Cells pretreated with or without ET1 for 2 passages and then induced for adipogenesis without ET1 for 21 d were analyzed by Oil Red O staining of lipid droplets (A), quantification of stained lipid droplets (B), and mRNA expression of fat-related markers (C); n = 3. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar, 200 µm.

ET1 primes BMSCs for osteogenic differentiation

Cells treated with ET1 for 2 passages and subsequently cultured in osteogenic differentiation medium without ET1 for 21 d were collected for analysis. Alizarin Red S staining (Fig. 3A) and quantification (Fig. 3B) showed that more calcium was produced in BMSCs pretreated with ET1 than those without ET1 pretreatment, whereas there were similar amounts of calcium deposition between ASCs with and without ET1 pretreatment. Expression levels of most of the bone-related markers OPN, ON, and IBSP in ET1-pretreated BMSCs were significantly higher than those in control cells after 21 d of osteogenic induction. In contrast, ASCs pretreated with ET1 and then induced for osteogenesis expressed similar or lower level of OPN, ON, and IBSP than those without ET1 pretreatment (Fig. 3C).

Figure 3.

Figure 3

Osteogenic differentiation of ET1-pretreated ASCs and BMSCs. Cells pretreated with or without ET1 for 2 passages and then induced for osteogenesis without ET1 for 21 d were analyzed by Alizarin Red S staining to detect matrix mineralization (A), quantification of calcium deposits (B), and mRNA expression of bone-related markers (C); n = 3. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar, 200 µm.

ET1 does not affect chondrogenic capacity of ASCs and BMSCs

For analysis of chondrogenesis, cells were treated with ET1 for 2 passages and then induced for chondrogenic differentiation without ET1 treatment for 21 d. Alcian Blue staining revealed that less GAGs were produced in chondrogenic pellets of donors 1 and 2 ASCs pretreated with ET1 than in those of control cells without ET1 pretreatment, whereas no difference in GAG staining was found between pretreated and control cells collected from donor 3 or from all BMSC donors (Fig. 4A). Consistently, the quantitative result of GAG content in ASC and BMSC culture measured by dimethylmethylene blue assay showed a similar trend compared to the result of Alcian Blue staining (Fig. 4B). In terms of mRNA expression results, there was no consistency in the expression levels of cartilage-related markers between pretreated and control ASCs or BMSCs among donors (Fig. 4C).

Figure 4.

Figure 4

Chondrogenic differentiation of ET1 pretreated ASCs and BMSCs. Cells pretreated with or without ET1 for 2 passages and then induced for chondrogenesis without ET1 for 21 d were analyzed by Alcian Blue staining of proteoglycans in pellets (A), quantification of GAG normalized with DNA content in pellets (B), and mRNA expression of cartilage-related markers (C); n = 3. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar, 200 µm.

Activation of endothelin receptors differentially directs lineage-specific differentiation of ET1-pretreated ASCs and BMSCs

To investigate how endothelin receptor activity is involved in directing lineage-specific differentiation of MSCs, BQ123, BQ788, and Bosentan were used to inhibit the activity of ETAR alone, ETBR alone, or both of the receptors of ASCs and BMSCs during ET1 treatment before differentiation induction. The results of Fig. 5 showing that ET1 increased adipogenesis of ASCs and osteogenesis of BMSCs were consistent with those shown in Figs. 2 and 3. With the addition of BQ123, BQ788, or Bosentan, the staining of Oil Red O in ET1-pretreated ASC culture induced for adipogenesis and the staining of Alizarin Red S in ET1-pretreated BMSCs culture induced for osteogenesis were decreased compared to those in ET1-pretreated culture without the antagonists induced for differentiation (Fig. 5A). Interestingly, the treatment of ET1 antagonists seemed not to affect osteogenesis of ET1-pretreated ASCs or adipogenesis of ET1-pretreated BMSCs (Fig. 5A). In addition to being consistent with the results of cytochemical staining, results of quantification of lipid droplets and calcium deposits further revealed that there was no significant difference in adipogenesis of ASCs and osteogenesis of BMSCs between BQ123/ET1- and BQ788/ET1-pretreated cells (Fig. 5B), suggesting that both ETAR+ and ETBR+ are involved in differential induction of adipogenic differentiation in ASCs and osteogenic differentiation in BMSCs by ET1.

Figure 5.

Figure 5

Adipogenic and osteogenic differentiation of ET1-pretreated ASCs and BMSCs treated with or without endothelin receptor antagonists. Activities of ETAR alone, ETBR alone, and both of receptors were attenuated by BQ123, BQ788, and Bosentan, respectively. A) Histologic staining of lipid droplets and calcium deposits by Oil Red O and Alizarin Red S, respectively, in culture after 21 d of differentiation induction. B) Quantification of lipid droplets and calcium deposits in culture after differentiation induction. C) Analysis of Western blot analysis detecting AKT and ERK1/2 activation in cells treated with or without ET1 and AKT or ERK inhibitors. GAPDH serves as internal control. D) Oil Red O staining for detection of lipid droplets and Alizarin Red S staining for detection of matrix mineralization. E) Quantification of lipid droplets and calcium deposits; n = 3. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar, 200 µm.

Analysis of ET1-activated downstream signaling pathways by Western blot analysis showed that AKT and ERK1/2 in both cell types were activated 1 h after ET1 treatment, that treatment of AKT and ERK1/2 inhibitors attenuated activation levels of the 2 signaling molecules, and that phosphorylation levels of the molecules shared similar patterns (Fig. 5C), suggesting that the AKT and ERK pathways are downstream signaling in ASCs and BMSCs activated by ET1. Furthermore, the result of cytochemical staining to determine effects of blocking the signaling pathways on adipogenesis and osteogenesis of ET1-pretreated cells showed that the intensity of Oil Red O or Alizarin Red S staining was decreased in adipogenic culture of ASCs and osteogenic culture of BMSCs treated with the signaling inhibitors compared to that in ET1-pretreated culture without inhibitor treatment, whereas that was comparable between ET1-pretreated cells with and without the inhibitors in osteogenic culture of ASCs and adipogenic culture of BMSCs treated with the signaling inhibitors (Fig. 5D). Quantification of lipid droplets and calcium deposits revealed consistent patterns of results for determining the association between signaling mechanisms and lineage-specific differentiation (Fig. 5E). These results, taken together, suggest that ET1 activates ETAR and/or ETBR and downstream AKT and ERK signaling to prime ASCs for adipogenesis or BMSCs for osteogenesis.

ASCs and BMSCs contain ETAR+ and ETBR+ subpopulations

Because our results showed that activities of both endothelin receptors were associated with specification of stem cell fate, we then assayed the amount of subpopulations of ASCs and BMSCs expressing ETAR and/or ETBR using flow cytometry. The mean percentage of the ETAR+ subpopulation in ASCs was 1.48 ± 0.09%, and that of BMSCs was 2.55 ± 0.38%. The mean percentage of the ETBR+ subpopulation in ASCs was 3.92 ± 0.45% and that of BMSCs was 9.63 ± 1.07% (Fig. 6A). Single cells selected from different zones of the density plot of flow cytometry were imaged to localize ETAR and ETBR on the cell surface. The results showed that both ASCs and BMSCs contained 4 subpopulations that expressed ETAR only, ETBR only, both of the receptors, and none of the receptors (Fig. 6B).

Figure 6.

Figure 6

Analysis of ETAR and ETBR expression on ASCs and BMSCs. A) Density plots of flow cytometry detecting ETAR+ and/or ETBR+ subpopulation and percentages of ETAR+ and/or ETBR+ subpopulation in ASCs and BMSCs. B) Single-cell fluorescent imaging of ETAR+ and/or ETBR+ subpopulation.

Subpopulations of ASCs and BMSCs induced by ET1 are prone to different lineage-specific differentiation

Subpopulations of ETAR+/ETBR−, ETAR−/ETBR+, and ETAR−/ETBR− isolation from ASCs and BMSCs were maintained in culture with ET1 before osteogenic and adipogenic induction (Fig. 7A). After 21 d of adipogenesis, results of mRNA expression showed that expression levels of PPARG2 and LPL in ETAR+/ETBR− ASCs were significantly higher than those in ETAR−/ETBR− cells, whereas expression levels of the transcripts in ETAR+/ETBR− and ETAR−/ETBR+ BMSCs were similar to or significantly lower than those in ETAR−/ETBR− cells (Fig. 7B). For osteogenesis, expression levels of both OPN and IBSP in ETAR+/ETBR− BMSCs were higher than those in ETAR−/ETBR− cells, whereas expression levels of the transcripts in ETAR+/ETBR− and ETAR−/ETBR+ ASCs were similar to those in ETAR−/ETBR− cells (Fig. 7B). To further confirm the findings, biochemical assays were performed to quantify the amount of lipid droplets and calcium deposits. The result showed that ETAR+/ETBR− and ETAR−/ETBR+ ASCs produced more lipid droplets but less calcium deposits than control ETAR−/ETBR− cells (Fig. 7C). In contrast, ETAR+/ETBR− and ETAR−/ETBR+ BMSCs produced more calcium deposits but less or comparable lipid droplets than control ETAR−/ETBR− cells (Fig. 7C). Consistently, the result of cytochemical staining showed similar patterns in which the intensity of Oil Red O staining in the culture of ETAR+/ETBR− and ETAR−/ETBR+ ASCs or that of Alizarin Red S staining in the culture of ETAR+/ETBR− and ETAR−/ETBR+ BMSCs was greater than that in the culture of ETAR−/ETBR− cells (Fig. 7D). Our results suggest that ET1-treated ETAR+/ETBR− and ETAR−/ETBR+ subpopulations in ASCs or BMSCs are more prone to adipogenesis or osteogenesis, respectively, than ET1-treated ETAR−/ETBR− cells.

Figure 7.

Figure 7

Adipogenic and osteogenic differentiation of isolated subpopulations of ASCs and BMSCs. Each subpopulation of cells was pretreated with ET1 for 2 passages before 21 d of differentiation induction. A) Isolation of ASC and BMSC subpopulations by FACS and subsequent setup of culture. B) Analysis of mRNA expression of fat- and bone-associated markers. C) Quantification of lipid droplets and calcium deposits. D) Oil Red O staining for detection of lipid droplets and Alizarin Red S staining for detection of matrix mineralization; n = 3. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar, 200 µm.

DISCUSSION

Our results demonstrate that both ETAR+/ETBR− and ETAR−/ETBR+ subpopulations of ASCs or BMSCs can be primed by ET1 for induced adipogenesis or osteogenesis, respectively, through activation of AKT and ERK signaling. Previous studies have shown that ET1 activates ETAR and downstream signaling molecules, such as AKT, ERK1/2, PKC, and protein kinase A, to regulate cell survival, migration, and proliferation (22, 35, 36). It has also been demonstrated that ETAR is involved in regulation of resistin secretion in adipocytes (37), remodeling of mesenchymal tissue and bone formation (38), and formation of postnatal trabecular bone in mice (39). ETBR is involved in regulation of fat tissue formation (40) and osteoblastic bone metastases and remodeling in prostate cancer (41). In the current study, our results showed that ETAR and ETBR are involved in the regulation of lineage specification of ASCs and BMSCs, and activation of either or both of the receptors differentially increases adipogenesis of ASCs or osteogenesis of BMSCs.

Although our findings suggest that ET1 is an anabolic factor for differentiation induction in MSCs, other published studies have concluded that ET1 functions as a catabolic factor. Such studies have shown that ET1 induces lipolysis in human and mice adipocytes (42, 43), and calcium deposition is reduced in mouse osteoblastic cells after ET1 treatment (44). Another discrepancy between our and previous findings is in the effect of ET1 on cell proliferation. Our results showed that cells pretreated with and without ET1 exhibit similar cell morphology and proliferation, consistent with our previously published findings (17). However, it has been reported that ET1 induces cells to increase proliferation (22). The discrepancy in the effect of ET1 on cell proliferation between these findings may be attributed to differences in cell types, ET1 doses, and frequencies and durations of ET1 administration in culture.

Our results indicate that ET1 can prime predifferentiated ASCs for enhanced adipogenic differentiation (Fig. 2). This finding seems to correlate with the clinical evidence that shows that ET1 is more abundant in obese patients than in nonobese patients (45). Our results also show that ET1 pretreatment up-regulates osteogenesis of BMSCs, while induction of the molecule does not affect osteogenesis of ASCs or adipogenesis of BMSCs. Although it is still not fully clear how lineage specification is differentially regulated between ASCs and BMSCs primed by ET1 induction, our current results provide data that clearly indicate ETAR and ETBR and their downstream signaling pathways, AKT and ERK, are involved in the regulation. Interestingly, the current results reveal that there is no significant difference in chondrogenesis of ASCs and BMSCs primed by ET1, which is different from our previously published finding that shows chondrogenesis of BMSCs pretreated with ET1 is up-regulated compared to that of control cells without ET1 pretreatment (17). The discrepancy in the effect of ET1 on chondrogenesis between our current and previous results is likely due to the use of different doses of ET1 to pretreat BMSCs in culture.

We have shown that blocking the activity of ETAR+, ETBR+, or both of the receptors reduces adipogenesis and osteogenesis in ET1-pretreated ASCs and BMSCs, respectively. These results indicate that ET1 regulates MSCs through both ETAR and ETBR. While previous studies have shown roles of the ETAR/ERK1/2 (46), ETAR/AKT (25), ETBR/ERK1/2 (47, 48), and ETBR/AKT (49) pathways in the regulation of non-MSC cells, our findings reveal that both ETAR and ETBR and downstream AKT and ERK signaling are involved in ET1-primied lineage specification of MSCs. While we have demonstrated that the AKT and ERK signaling pathways are activated by ET1 in this study, and given that other signaling pathways, such as PKC and focal adhesion kinase, can also be activated by ET1 (50, 51), it would be desired in future studies to determine if other signaling pathways are involved and whether these pathways undergo crosstalk.

Whether adult MSCs collected from different tissues, such as fat and bone marrow, are the same cell type but reside at different body locations has been debated for years. A previous study comparing cell proliferation, senescence, and the capacity of multilineage differentiation between ASCs and BMSCs isolated from the same donor has revealed that the 2 cells sharing similar biologic characteristics are likely to be the same cell type (52). Similarly, another study has demonstrated that ASCs and BMSCs exhibiting comparable capacity of chondrogenic differentiation are similar to each other (53). However, other research evidence indicates that MSCs from different tissues are not the same; they are different in expression of surface markers and transcripts as well as differentiation potential. For example, researchers have demonstrated differences in the differentiation potency among MSCs isolated from amnion, chorion, and umbilical cord (54) and in the expression profile of markers among MSCs derived from bone marrow, adipose, placenta, and thymus (55). In our study, we demonstrate that in response to induction of the same molecule ET1, ASCs and BMSCs are primed to preferentially differentiate into adipocytes and osteoblasts, respectively, consistent with findings of a previous study using PDGF-BB (16), suggesting that the 2 cells are likely to be different MSCs in tissues.

In this study, we did not use matched ASCs and BMSCs from the same donor for comparison because it is challenging to find a donor available for MSC collection from 2 different tissues. To overcome the limitation, we could have used cells from nonhuman animals; however, considering the clinical relevance and translational potential, we decided to use human cells for this study. Our solution to the limitation is that we used samples from multiple donors for analysis to reduce any potential impact of the variable caused by difference in ASC and BMSC donors on the data to ensure our results are reliable.

CONCLUSIONS

Our study found that ET1 primes ASCs for adipogenesis and BMSCs for osteogenesis through activation of both ETAR and ETBR and downstream AKT and ERK signaling. While whole ASCs and BMSCs contain small fractions of ETAR+ and ETBR+ populations, the ETAR+ and ETBR+ subpopulations in ASCs or those in BMSCs are more responsive to ET1 induction than other subpopulations to be primed for induction of adipogenesis or osteogenesis, respectively. Taken together, our findings provide insight into how MSCs in different tissues are differentially regulated by a ubiquitous physiologic molecule; our findings also indicate that the fate of MSC differentiation is closely associated with the tissue-specific microenvironment.

ACKNOWLEDGMENTS

The authors thank E.-L. Hsieh (Shih Chien University, Taipei, Taiwan), J. L. Michel (University of Wisconsin–La Crosse, WI, USA), and C. Ma (Wellesley College, MA, USA) for their help in this study. Research reported in this publication was partially supported by the U.S. National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR064803). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors declare no conflicts of interest.

Glossary

AKT

protein kinase B

APN

adiponectin

ASC

adipose-derived stem cell

BMSC

bone marrow–derived mesenchymal stem cell

COL2

collagen type 2

EC

endothelial cell

ET1

endothelin-1

ETAR

endothelin receptor type A

ETBR

endothelin receptor type B

FACS

fluorescence-activated cell sorting

FBS

fetal bovine serum

GAG

glycosaminoglycan

IBSP

integrin binding sialoprotein

LPL

lipoprotein lipase

MAPK

mitogen-activated protein kinase

MSC

mesenchymal stem cell

ON

osteonectin

OPN

osteopontin

PDGF-BB

platelet-derived growth factor BB

PKC

protein kinase C

PPARG2

peroxisome proliferator-activated receptor γ 2

SOX9

sex-determining region Y-box 9

UBC

ubiquitin C

AUTHOR CONTRIBUTIONS

M.-S. Lee and W.-J. Li designed research; M.-S. Lee, H. Yuan, H. Jiao, T.-L. Tsai, and M. W. Squire performed research; M.-S. Lee, H. Yuan, and W.-J. Li analyzed data; and M.-S. Lee, J. Wang, and W.-J. Li wrote the manuscript.

REFERENCES

  • 1.Deans R. J., Moseley A. B. (2000) Mesenchymal stem cells: biology and potential clinical uses. Exp. Hematol. 28, 875–884 [DOI] [PubMed] [Google Scholar]
  • 2.Dimarino A. M., Caplan A. I., Bonfield T. L. (2013) Mesenchymal stem cells in tissue repair. Front. Immunol. 4, 201 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Robertson J. A. (2001) Human embryonic stem cell research: ethical and legal issues. Nat. Rev. Genet. 2, 74–78 [DOI] [PubMed] [Google Scholar]
  • 4.Pittenger M. F., Mackay A. M., Beck S. C., Jaiswal R. K., Douglas R., Mosca J. D., Moorman M. A., Simonetti D. W., Craig S., Marshak D. R. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284, 143–147 [DOI] [PubMed] [Google Scholar]
  • 5.Wu Y., Chen L., Scott P. G., Tredget E. E. (2007) Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 25, 2648–2659 [DOI] [PubMed] [Google Scholar]
  • 6.Jin H. J., Bae Y. K., Kim M., Kwon S. J., Jeon H. B., Choi S. J., Kim S. W., Yang Y. S., Oh W., Chang J. W. (2013) Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int. J. Mol. Sci. 14, 17986–18001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Shi S., Gronthos S. (2003) Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. J. Bone Miner. Res. 18, 696–704 [DOI] [PubMed] [Google Scholar]
  • 8.Tang W., Zeve D., Suh J. M., Bosnakovski D., Kyba M., Hammer R. E., Tallquist M. D., Graff J. M. (2008) White fat progenitor cells reside in the adipose vasculature. Science 322, 583–586 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Méndez-Ferrer S., Michurina T. V., Ferraro F., Mazloom A. R., Macarthur B. D., Lira S. A., Scadden D. T., Ma’ayan A., Enikolopov G. N., Frenette P. S. (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466, 829–834 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Crisan M., Yap S., Casteilla L., Chen C. W., Corselli M., Park T. S., Andriolo G., Sun B., Zheng B., Zhang L., Norotte C., Teng P. N., Traas J., Schugar R., Deasy B. M., Badylak S., Buhring H. J., Giacobino J. P., Lazzari L., Huard J., Péault B. (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3, 301–313 [DOI] [PubMed] [Google Scholar]
  • 11.Caplan A. I. (2017) New MSC: MSCs as pericytes are sentinels and gatekeepers. J. Orthop. Res. 35, 1151–1159 [DOI] [PubMed] [Google Scholar]
  • 12.Traktuev D. O., Merfeld-Clauss S., Li J., Kolonin M., Arap W., Pasqualini R., Johnstone B. H., March K. L. (2008) A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ. Res. 102, 77–85 [DOI] [PubMed] [Google Scholar]
  • 13.Nassiri S. M., Rahbarghazi R. (2014) Interactions of mesenchymal stem cells with endothelial cells. Stem Cells Dev. 23, 319–332 [DOI] [PubMed] [Google Scholar]
  • 14.Fiedler J., Röderer G., Günther K. P., Brenner R. E. (2002) BMP-2, BMP-4, and PDGF-bb stimulate chemotactic migration of primary human mesenchymal progenitor cells. J. Cell. Biochem. 87, 305–312 [DOI] [PubMed] [Google Scholar]
  • 15.Mayer H., Bertram H., Lindenmaier W., Korff T., Weber H., Weich H. (2005) Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: autocrine and paracrine role on osteoblastic and endothelial differentiation. J. Cell. Biochem. 95, 827–839 [DOI] [PubMed] [Google Scholar]
  • 16.Lin R. Z., Moreno-Luna R., Li D., Jaminet S. C., Greene A. K., Melero-Martin J. M. (2014) Human endothelial colony-forming cells serve as trophic mediators for mesenchymal stem cell engraftment via paracrine signaling. Proc. Natl. Acad. Sci. USA 111, 10137–10142 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Tsai T. L., Wang B., Squire M. W., Guo L. W., Li W. J. (2015) Endothelial cells direct human mesenchymal stem cells for osteo- and chondro-lineage differentiation through endothelin-1 and AKT signaling. Stem Cell Res. Ther. 6, 88 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411–415 [DOI] [PubMed] [Google Scholar]
  • 19.Nelson J. B., Nguyen S. H., Wu-Wong J. R., Opgenorth T. J., Dixon D. B., Chung L. W., Inoue N. (1999) New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 53, 1063–1069 [DOI] [PubMed] [Google Scholar]
  • 20.Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. (1990) Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348, 730–732 [DOI] [PubMed] [Google Scholar]
  • 21.Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. (1990) Cloning of a cDNA encoding a non–isopeptide-selective subtype of the endothelin receptor. Nature 348, 732–735 [DOI] [PubMed] [Google Scholar]
  • 22.Rosanò L., Spinella F., Bagnato A. (2013) Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 13, 637–651 [DOI] [PubMed] [Google Scholar]
  • 23.Polyak K., Weinberg R. A. (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265–273 [DOI] [PubMed] [Google Scholar]
  • 24.Khimji A. K., Rockey D. C. (2010) Endothelin—biology and disease. Cell. Signal. 22, 1615–1625 [DOI] [PubMed] [Google Scholar]
  • 25.Cianfrocca R., Rosanò L., Spinella F., Di Castro V., Natali P. G., Bagnato A. (2010) Beta-arrestin-1 mediates the endothelin-1–induced activation of Akt and integrin-linked kinase. Can. J. Physiol. Pharmacol. 88, 796–801 [DOI] [PubMed] [Google Scholar]
  • 26.Galié N., Manes A., Branzi A. (2004) The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res. 61, 227–237 [DOI] [PubMed] [Google Scholar]
  • 27.Spinella F., Rosanò L., Del Duca M., Di Castro V., Nicotra M. R., Natali P. G., Bagnato A. (2010) Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1α in melanoma cells. PLoS One 5, e11241 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 28.Lee R. H., Kim B., Choi I., Kim H., Choi H. S., Suh K., Bae Y. C., Jung J. S. (2004) Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell. Physiol. Biochem. 14, 311–324 [DOI] [PubMed] [Google Scholar]
  • 29.Liao H. T., Chen C. T. (2014) Osteogenic potential: comparison between bone marrow and adipose-derived mesenchymal stem cells. World J. Stem Cells 6, 288–295 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Hass R., Kasper C., Böhm S., Jacobs R. (2011) Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue–derived MSC. Cell Commun. Signal. 9, 12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Chen S., Fu P., Cong R., Wu H., Pei M. (2015) Strategies to minimize hypertrophy in cartilage engineering and regeneration. Genes Dis. 2, 76–95 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Sakaguchi Y., Sekiya I., Yagishita K., Muneta T. (2005) Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheum. 52, 2521–2529 [DOI] [PubMed] [Google Scholar]
  • 33.Diekman B. O., Rowland C. R., Lennon D. P., Caplan A. I., Guilak F. (2010) Chondrogenesis of adult stem cells from adipose tissue and bone marrow: induction by growth factors and cartilage-derived matrix. Tissue Eng Part A 16, 523–533 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Brown P. T., Squire M. W., Li W. J. (2014) Characterization and evaluation of mesenchymal stem cells derived from human embryonic stem cells and bone marrow. Cell Tissue Res. 358, 149–164 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Nelson J., Bagnato A., Battistini B., Nisen P. (2003) The endothelin axis: emerging role in cancer. Nat. Rev. Cancer 3, 110–116 [DOI] [PubMed] [Google Scholar]
  • 36.Ohkita M., Tawa M., Kitada K., Matsumura Y. (2012) Pathophysiological roles of endothelin receptors in cardiovascular diseases. J. Pharmacol. Sci. 119, 302–313 [DOI] [PubMed] [Google Scholar]
  • 37.Zhong Q., Lin C. Y., Clarke K. J., Kemppainen R. J., Schwartz D. D., Judd R. L. (2002) Endothelin-1 inhibits resistin secretion in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 296, 383–387 [DOI] [PubMed] [Google Scholar]
  • 38.Tanaka S., Mori M., Ehara Y., Adachi M., Sumitomo S. (2017) Signaling of endothelin involves bone and soft tissue remodeling by modulating wound healing and tumor progression. J. Oral Maxillofac. Surg. Med. Pathol. 29, 85–99 [Google Scholar]
  • 39.Clines G. A., Mohammad K. S., Grunda J. M., Clines K. L., Niewolna M., McKenna C. R., McKibbin C. R., Yanagisawa M., Suva L. J., Chirgwin J. M., Guise T. A. (2011) Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor. J. Bone Miner. Res. 26, 2523–2536 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Mundy A. L., Haas E., Bhattacharya I., Widmer C. C., Kretz M., Hofmann-Lehmann R., Minotti R., Barton M. (2007) Fat intake modifies vascular responsiveness and receptor expression of vasoconstrictors: implications for diet-induced obesity. Cardiovasc. Res. 73, 368–375 [DOI] [PubMed] [Google Scholar]
  • 41.Nadiminty N., Lou W., Lee S. O., Mehraein-Ghomi F., Kirk J. S., Conroy J. M., Zhang H., Gao A. C. (2006) Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Clin. Cancer Res. 12, 1420–1430 [DOI] [PubMed] [Google Scholar]
  • 42.Juan C. C., Chang C. L., Lai Y. H., Ho L. T. (2005) Endothelin-1 induces lipolysis in 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab. 288, E1146–E1152 [DOI] [PubMed] [Google Scholar]
  • 43.Eriksson A. K., van Harmelen V., Stenson B. M., Aström G., Wåhlén K., Laurencikiene J., Rydén M. (2009) Endothelin-1 stimulates human adipocyte lipolysis through the ET A receptor. Int. J. Obes. 33, 67–74 [DOI] [PubMed] [Google Scholar]
  • 44.Hiruma Y., Inoue A., Shiohama A., Otsuka E., Hirose S., Yamaguchi A., Hagiwara H. (1998) Endothelins inhibit the mineralization of osteoblastic MC3T3-E1 cells through the A-type endothelin receptor. Am. J. Physiol. 275, R1099–R1105 [DOI] [PubMed] [Google Scholar]
  • 45.Van Harmelen V., Eriksson A., Aström G., Wåhlén K., Näslund E., Karpe F., Frayn K., Olsson T., Andersson J., Rydén M., Arner P. (2008) Vascular peptide endothelin-1 links fat accumulation with alterations of visceral adipocyte lipolysis. Diabetes 57, 378–386 [DOI] [PubMed] [Google Scholar]
  • 46.Dibra D., Xia X., Mitra A., Cutrera J. J., Lozano G., Li S. (2016) Mutant p53 in concert with an interleukin-27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice. Hepatology 63, 1000–1012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Yamaguchi T., Murata Y., Fujiyoshi Y., Doi T. (2003) Regulated interaction of endothelin B receptor with caveolin-1. Eur. J. Biochem. 270, 1816–1827 [DOI] [PubMed] [Google Scholar]
  • 48.Zhang J., Yang W., Hu B., Wu W., Fallon M. B. (2014) Endothelin-1 activation of the endothelin B receptor modulates pulmonary endothelial CX3CL1 and contributes to pulmonary angiogenesis in experimental hepatopulmonary syndrome. Am. J. Pathol. 184, 1706–1714 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Tang L., Luo B., Patel R. P., Ling Y., Zhang J., Fallon M. B. (2007) Modulation of pulmonary endothelial endothelin B receptor expression and signaling: implications for experimental hepatopulmonary syndrome. Am. J. Physiol. Lung Cell. Mol. Physiol. 292, L1467–L1472 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Clerk A., Bogoyevitch M. A., Anderson M. B., Sugden P. H. (1994) Differential activation of protein kinase C isoforms by endothelin-1 and phenylephrine and subsequent stimulation of p42 and p44 mitogen-activated protein kinases in ventricular myocytes cultured from neonatal rat hearts. J. Biol. Chem. 269, 32848–32857 [PubMed] [Google Scholar]
  • 51.Dawson L. A., Maitland N. J., Turner A. J., Usmani B. A. (2004) Stromal–epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. Br. J. Cancer 90, 1577–1582 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.De Ugarte D. A., Morizono K., Elbarbary A., Alfonso Z., Zuk P. A., Zhu M., Dragoo J. L., Ashjian P., Thomas B., Benhaim P., Chen I., Fraser J., Hedrick M. H. (2003) Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs (Print) 174, 101–109 [DOI] [PubMed] [Google Scholar]
  • 53.Winter A., Breit S., Parsch D., Benz K., Steck E., Hauner H., Weber R. M., Ewerbeck V., Richter W. (2003) Cartilage-like gene expression in differentiated human stem cell spheroids: a comparison of bone marrow-derived and adipose tissue-derived stromal cells. Arthritis Rheum. 48, 418–429 [DOI] [PubMed] [Google Scholar]
  • 54.Kwon A., Kim Y., Kim M., Kim J., Choi H., Jekarl D. W., Lee S., Kim J. M., Shin J. C., Park I. Y. (2016) Tissue-specific differentiation potency of mesenchymal stromal cells from perinatal tissues. Sci. Rep. 6, 23544 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Musina R. A., Bekchanova E. S., Sukhikh G. T. (2005) Comparison of mesenchymal stem cells obtained from different human tissues. Bull. Exp. Biol. Med. 139, 504–509 [DOI] [PubMed] [Google Scholar]

Articles from The FASEB Journal are provided here courtesy of The Federation of American Societies for Experimental Biology

RESOURCES